Ghafur Abdul, Vidyalakshmi P R, Priyadarshini K, Easow Jose M, Raj Revathi, Raja T
Department of Infectious Diseases, Apollo Speciality Hospitals, Chennai, India.
Department of Hemato-Oncology, Apollo Speciality Hospitals, Chennai, India.
South Asian J Cancer. 2013 Oct;2(4):211-5. doi: 10.4103/2278-330X.119912.
Although Elizabethkingia meningoseptica (Chryseobacterium meningosepticum) infections in immunocompromised hosts have been recognised, clinical data detailing these infections remain limited, especially from India. Antimicrobial susceptibility data on E. meningoseptica remain very limited, with no established breakpoints by Clinical and Laboratory Standards Institute (CLSI). The organism is usually multidrug resistant to antibiotics usually prescribed for treating Gram-negative bacterial infections, a serious challenge to the patient and the treating clinicians.
The analysis was done in a tertiary care oncology and stem cell transplant center. Susceptibility testing and identification of E. meningoseptica was done using Vitek auto analyzer. Records of immunocompromised patients with E. meningoseptica bacteremia were analysed from January 2009 to March 2012.
A total of 29 E. meningoseptica bacteremia cases were documented between 2009 and 2012. Eleven patients were immunocompromised. Three were post stem cell transplant and one was post cord blood transplant. The mean age of the patients was 48.4 years. Mean Charlson's comorbidity index was 5.7. Four had solid organ malignancies, five had hematological malignancies, and two had lymphoreticular malignancy. Eight patients had received chemotherapy. Mean Apache II score was 18. Mean Pitts score for bacteremia was 4.7. Two were neutropenic (one post SCT, one MDS post chemo) with a mean white blood cell (WBC) count of 450/mm(3) . Ten had a line at the time of bacteremia. Mean duration of the line prior to bacteremia was 8 days. Eight had line-related bacteremia. Three had pneumonia with secondary bacteremia. All received combination therapy with two or more antibiotics which included cotrimoxazole, rifampicin, piperacillin-tazobactam, tigecycline, or cefepime-tazobactam. All the isolates showed in vitro resistance to ciprofloxacin. Five patients died, but a multivariate analysis was not done to calculate the attributable mortality.
In our study, central line was the commonest risk factor for E. meningosepticum bacteremia, although a multivariate analysis was not done. There has not been much of a change in the susceptibility pattern of these organisms over 3 years, with good susceptibility to piperacillin-tazobactam and cotrimoxazole. Even though uncommon, E. meningoseptica is an important pathogen, especially in immunocompromised hosts with indwelling devices.
尽管免疫功能低下宿主中的脑膜败血伊丽莎白金菌(以前称为脑膜败血金黄杆菌)感染已得到认识,但详细描述这些感染的临床数据仍然有限,尤其是来自印度的数据。脑膜败血伊丽莎白金菌的药敏数据仍然非常有限,临床和实验室标准协会(CLSI)尚未确立其断点。该菌通常对用于治疗革兰氏阴性菌感染的常用抗生素具有多重耐药性,这对患者和治疗临床医生构成了严峻挑战。
本分析在一家三级医疗肿瘤与干细胞移植中心进行。使用Vitek自动分析仪对脑膜败血伊丽莎白金菌进行药敏试验和鉴定。分析了2009年1月至2012年3月期间免疫功能低下的脑膜败血伊丽莎白金菌血症患者的记录。
2009年至2012年期间共记录了29例脑膜败血伊丽莎白金菌血症病例。11例患者免疫功能低下。3例为干细胞移植后,1例为脐血移植后。患者的平均年龄为48.4岁。查尔森合并症指数平均为5.7。4例患有实体器官恶性肿瘤,5例患有血液系统恶性肿瘤,2例患有淋巴网状恶性肿瘤。8例患者接受了化疗。急性生理与慢性健康状况评分系统(Apache II)平均评分为18分。菌血症的匹兹堡评分平均为4.7分。2例为中性粒细胞减少(1例干细胞移植后,1例化疗后骨髓增生异常综合征),平均白细胞(WBC)计数为450/mm³。10例在发生菌血症时有中心静脉导管。菌血症发生前中心静脉导管的平均留置时间为8天。8例为导管相关菌血症。3例有肺炎并继发菌血症。所有患者均接受了两种或更多种抗生素的联合治疗,这些抗生素包括复方新诺明、利福平、哌拉西林-他唑巴坦、替加环素或头孢吡肟-他唑巴坦。所有分离株均显示对环丙沙星体外耐药。5例患者死亡,但未进行多因素分析以计算归因死亡率。
在我们的研究中,尽管未进行多因素分析,但中心静脉导管是脑膜败血伊丽莎白金菌血症最常见的危险因素。在3年期间,这些菌株的药敏模式变化不大,对哌拉西林-他唑巴坦和复方新诺明敏感性良好。尽管不常见,但脑膜败血伊丽莎白金菌是一种重要的病原体,尤其是在有留置装置的免疫功能低下宿主中。